Stock Quote        
  Join        Login  
logo

Pfizer (PFE) Fined $60M Over Foreign Bribery Probe

 August 07, 2012 02:00 PM
 

(By Balachander) Pfizer Inc. (NYSE:PFE) will pay a fine totaling $60 million to resolve allegations that its employees and agents bribed foreign officials to boost the company's business.

The Securities and Exchange Commission (SEC) alleges that Pfizer's overseas subsidiaries made improper payments to government officials in Bulgaria, Croatia, Kazakhstan and Russia. Employees in each of the involved subsidiaries tried to conceal the true nature of the transactions by improperly recording them on the books and records of the respective subsidiaries.

According to the SEC's complaint against Pfizer, the misconduct dates back as far as 2001. Pfizer made an initial voluntary disclosure of misconduct by its subsidiaries to the SEC and U.S. Department of Justice in October 2004, and fully cooperated with SEC investigators.

"Pfizer subsidiaries in several countries had bribery so entwined in their sales culture that they offered points and bonus programs to improperly reward foreign officials who proved to be their best customers," said Kara Brockmeyer, Chief of the SEC Enforcement Division's Foreign Corrupt Practices Act Unit.

Pfizer agreed to pay more than $45 million under the terms of the settlement with the SEC. Pfizer's HCP subsidiary will pay $15 million to resolve similar bribery probe by the Justice Department.

"Pfizer took short cuts to boost its business in several Eurasian countries, bribing government officials in Bulgaria, Croatia, Kazakhstan and Russia to the tune of millions of dollars," said Principal Deputy Assistant Attorney General Raman of the Justice Department's Criminal Division.

Pfizer neither admitted nor denied the allegations.

The stock retreated 1.65 percent to trade at $23.86 on Tuesday. Over the past year, shares have been trading between $16.63 and $24.49.


Rich
i On The Market - Daily Newsletter
Every trading day, be ready to attack the market instead of reacting to the market.

You will know where the key technical resistance and support levels are and what the market is likely to do next. iStock will arm you with a target list of stocks to buy and sell - right now - based on our exclusive, proprietary trading models.

Two Week FREE Trial


Signup for i on the market daily edition


Advertisement

Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

Advertisement
Connect with iStockAnalyst
Popular Articles
Recent Research and Quote
Advertisement
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.